ANGO

AngioDynamics, Inc.

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.

AngioDynamics, Inc. (ANGO) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Value (D+). The rating has held at C+ for 14 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
D+
Factor Score 1.5 / 5.0
Growth
C+
Factor Score 2.7 / 5.0
Profitability
B+
Factor Score 3.6 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -103.9
EV / EBITDA 359.6
Rev Growth YoY 6.9%
Gross Margin 55.3%
Price Return 3M -25.5%
Price Return 12M -4.2%
Catalyst Signal 0.00
Market Cap $495.4M
TTM Revenue $325.4M
Price / Sales 1.5
ROE -19.2%

Historical Factor Score Progression

Held C+ for 14 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 D+ (1.5) C+ (2.7) B+ (3.6) C (2.4) C+ (2.6) C+ (2.6)
2026-11-10 D+ (1.5) C+ (2.7) B+ (3.6) C+ (2.5) C+ (2.6) C+ (2.6)
2026-11-03 D+ (1.5) C+ (2.7) B+ (3.6) B (3.2) C+ (2.7) C+ (2.7)
2026-10-27 D+ (1.5) C+ (2.7) B+ (3.6) B- (3.1) C+ (2.6) C+ (2.7)
2026-10-20 D+ (1.5) C+ (2.7) B+ (3.6) B- (3.0) C+ (2.6) C+ (2.7)
Page 1 of 8
…